Adoptive Immunotherapy in Postoperative Hepatocellular Carcinoma A Systemic Review 英文参考文献.docVIP

下载本文档

2
0
约2.21万字
约 7页
2017-05-11 发布于上海
举报
版权申诉

Adoptive Immunotherapy in Postoperative Hepatocellular Carcinoma A Systemic Review 英文参考文献.doc

1、本文档共7页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

Adoptive Immunotherapy in Postoperative Hepatocellular Carcinoma A Systemic Review 英文参考文献

AdoptiveImmunotherapyinPostoperative HepatocellularCarcinoma:ASystemicReview FengXie1,2.,XinjiZhang1.,HuiLi1.,TaoZheng2,FengXu2,RongxiShen2,LongYan2,JiameiYang2*, JiaHe1* 1Department of Health Statistics, The Second Military Medical University, Shanghai, China, 2Department of Special Treatment and Liver Transplantation, Eastern HepatobiliarySurgeryHospital,TheSecondMilitaryMedicalUniversity,Shanghai,China Abstract Purpose:Theeffectivenessofimmunotherapyforpostoperativehepatocellularcarcinomapatientsisstillcontroversial.To addressthisissue,wedidasystemicreviewoftheliteraturesandanalyzedthedatawithemphasisontherecurrenceand survival. Methods: We searched six randomized controlled trials that included adoptive immunotherapy in the postoperative management of hepatocellular carcinoma and compared with non-immunotherapy postoperation. A meta-analysis was carriedouttoexamineone-and3-yearrecurrenceandsurvival. Results: The overall analysis revealed significantly reduced risk of 1-year recurrence in patients receiving adoptive immunotherapy(OR=0.35;95%CI,0.17to0.71;p=0.003),inthattheriskof3-yearrecurrencewithapooledORestimated at 0.31 (95% CI 0.16 to 0.61; p=0.001). However, no statistically significant difference was observed for 3-year survival betweengroupswithadoptiveimmunotherapyandwithoutadjuvanttreatment(OR=0.91;95%CI,0.45to1.84;P=0.792). Conclusions: Adjuvant immunotherapywithcytokine induced killer cells orlymphokine activated killer cells may reduce recurrenceinpostoperativehepatocellularcarcinomapatients,butmaynotimprovesurvival. Citation:XieF,ZhangX,LiH,ZhengT,XuF,etal.(2012)AdoptiveImmunotherapyinPostoperativeHepatocellularCarcinoma:ASystemicReview.PLoSONE7(8): e42879.doi:10.1371/journal.pone.0042879 Editor:DevanandSarkar,VirginiaCommonwealthUniversity,UnitedStatesofAmerica ReceivedMarch28,2012;AcceptedJuly12,2012;PublishedAugust15,2012 Copyright:?2012Xieetal.Thisisanopen-accessarticledistributedunderthetermsoftheCreativeCommonsAttributionLicense,whichpermits